Skip to main content
. 2021 Jul 7;100(9):2387–2398. doi: 10.1007/s00277-021-04565-1

Table 2.

Frequency of hematopoietic cell transplantation (HCT) in patients with AML

All patients n (%)  ≤ 60 years, n (%)  > 60 years, n (%)
1621 740 881
Disease stage CR1 Refractory Relapse/CR2 CR1 Refractory Relapse/CR2 CR1 Refractory Relapse/CR2
n 1144 238 582/227 586 56 235/128 558 182 347/99
HCT 427 (37.3) 72 (30.2) 155 (26.6/68.3) 273 (46.6) 39 (69.6) 108 (46.0/84.4) 154 (27.6) 33 (18.1) 47 (13.8/47.4)
Allogeneic HCT 395 (92.5) 72 151 (97.4) 241 (88.3) 39 107 (99.1) 154 (100) 33 44 (93.6)
Related donor 112 (28.4) 20 (27.8) 23 (15.2) 82 (34.0) 12 (30.8) 18 (17.5)* 30 (19.5) 8 (24.2) 5 (11.4)#
Unrelated donor 282 (71.4) 51 (70.8) 124 (82,1) 158 (66.1) 26 (66.7) 86 (82.6)* 124 (80.6) 25 (75.8) 38 (86.4)#
MMUD 77 (27.3) 16 (31.4) 41 (33.1) 41 (25.9) 9 (34.6) 36 (42.3)** 36 (29.0) 7 (28.0) 5 (13.1)##
NMAC 164 (41.5) 14 (19.4) 39 (25.8) 44 (18.3) 5 (12.8) 21 (19.6) 120 (77.9) 9 (27.3) 18 (40.9)
Autologous HCT 32 (7.5) - 4 (2.6) 32 (11.7) - 1 (0.9) - - 3 (6.4)

Information missing on: *3 donors, **9 × HLA matching, #1 donor, and ##1 × HLA matching missing

Abbreviations: MMUD, mismatched donor; NMAC, non-myeloablative conditioning HCT